Immunological Targeting of Tumor Initiating Prostate Cancer Cells
Abstract
These studies are aimed at targeting a population of luminal epithelial cells that repopulate the prostate gland after androgen-ablation and give rise to castrate-resistant disease prostate cancer. In two specific aims, we proposed to first identify novel antigenic targets on these castrate resistant luminal epithelial cells (CRLEC), then to test these antigens with state-of-the-art vaccines. During the first year of funding we ve made significant progress on Aim 1, and microarray studies to identify antigenic targets are in progress at the JHU core facility. Our second model, involving implanted tumor cells in mice, was a bit more challenging and we were unable to sort CRLEC with standard technology. Instead, we had to work around that issue by generating a fluorescently tagged cell line (mCherry-MycCap). That cell line has been established and characterized, and the additional CRLEC antigen studies that are part of Aim 1 are currently making good progress.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2014
- Accession Number
- ADA613701
Entities
People
- Charles G Drake
Organizations
- Johns Hopkins University